Carl J
About Carl J
Press coverage of the DeepCyte launch names Carl J. G. Evertsz as a medtech executive, former CEO and investor. Those articles are the source for the DeepCyte details on this page, and they match the DeepCyte seed round on the Lounge deals desk.
Details of the companies he has built or run are not given in the sources we found. Founders can check his LinkedIn profile for his full work history.
DeepCyte is the one AI round we could confirm. The company launched on April 9, 2026 with $1.5M in seed funding. Press releases say the round was supported by Evertsz, who also serves as Board Chair. Dealroom lists him as a co-founder alongside CEO Theodore Alexandrov and COO Shawn Owens. Another outlet describes him as leading the round.
DeepCyte is a techbio company based in Delaware and Copenhagen. It combines MetaCore, a single-cell metabolomics platform, with DeeImmuno, an AI model that predicts drug toxicity. In the company's validation on 100 held-out drugs, DeeImmuno predicted 17 toxicity mechanisms with 94% accuracy.
His share of the $1.5M has not been published.
The only public data point is DeepCyte: a seed-stage investment in AI applied to drug safety and biopharma. He took a board chair role alongside the investment. We found no public statements from him on check size, preferred stages, geographies or what he looks for in a pitch. Founders should treat those as unconfirmed and ask him directly.
- DeepCyte: AI-powered single-cell toxicology tools for drug development. He backed its $1.5M seed round in April 2026 and serves as Board Chair.
- prnewswire.com/news-releases/deepcyte-raises-1-5m-to-bring-single-cell
- deepcyte.bio/news-announcements/deepcyte-raises-1-5m-to-bring-single-c
- app.dealroom.co/companies/deepcyte
- genomeweb.com/business-news/single-cell-drug-toxicity-prediction-start
- raising.fi/news/deepcyte-seed-april-2026
- justainews.com/companies/funding-news/deepcyte-raises-1-5m-to-build-ai
Investing activity
Carl J appears in 1 AI deal tracked by the Lounge deals desk. The rounds are mostly Seed, with a median round size of $2M. The most recent is DeepCyte (Seed, $1.5M, Apr 2026).
Deals
Frequently asked questions about Carl J
Has Carl J invested in AI startups?
Yes. Carl J. G. Evertsz was named as an investor in DeepCyte's $1.5M seed round, announced in April 2026. DeepCyte builds AI tools that predict drug toxicity.
What is Carl J's background?
Press coverage of the DeepCyte launch describes Carl J. G. Evertsz as a medtech executive, former CEO and investor. Further career details are not in the sources we reviewed.
What check size does Carl J write?
His check size is not public. DeepCyte's seed round totaled $1.5M, and his share of it has not been disclosed.
What stage does Carl J invest in?
His only confirmed AI investment is a seed round. No public statement on preferred stages was found.
Does Carl J take a board role in companies he backs?
At DeepCyte he serves as Board Chair, according to the company's announcement. We have not confirmed whether this is his usual practice.
How can founders contact Carl J?
His LinkedIn profile is the only public channel we could confirm. We did not find a personal website or an X account.
Is Carl J an angel investor?
Yes. Carl J invests personally as an angel.
What AI companies has Carl J invested in?
Carl J's AI investments include DeepCyte. The 1 round on Lounge are listed on this page with amounts, dates and co-investors.
What stage does Carl J invest at?
In the rounds tracked on Lounge, Carl J has invested at Seed, with a median round of $2M.
How can founders reach Carl J?
Founders on Lounge can see Carl J's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with them under Warm Paths, and add Carl J to their Investor Pipeline to track the conversation.